Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Involvement of Lymphocyte Type B in Amyotrophic Lateral Sclerosis (ALS)

This study is enrolling participants by invitation only.
Sponsor:
Information provided by:
Rambam Health Care Campus
ClinicalTrials.gov Identifier:
NCT00846560
First received: February 15, 2009
Last updated: February 17, 2009
Last verified: February 2009
  Purpose
The involvement of Lymphocyte type B in Amyotrophic lateral sclerosis (ALS) patients will be compared to lymphocyte in healthy subjects.

Condition
Amyotrophic Lateral Sclerosis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Involvement of Lymphocyte Type B in Amyotrophic Lateral Sclerosis (ALS)

Resource links provided by NLM:


Further study details as provided by Rambam Health Care Campus:

Estimated Enrollment: 20
Study Start Date: August 2008
Estimated Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
1 ALS patients
2 Healthy subjects

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Amyotrophic lateral sclerosis and Healthy subjects
Criteria

Inclusion Criteria:

  • ALS patients who could sign ICF.

Exclusion Criteria:

  • No ALS patients age less than 18 years.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00846560

Locations
Israel
Rambam Medical center, Neurology Department
Haifa, Israel
Sponsors and Collaborators
Rambam Health Care Campus
  More Information

Responsible Party: Prof. David Yarnitsky, Rambam medical center
ClinicalTrials.gov Identifier: NCT00846560     History of Changes
Other Study ID Numbers: ALS04CTIL 
Study First Received: February 15, 2009
Last Updated: February 17, 2009
Health Authority: Israel: Ministry of Health

Additional relevant MeSH terms:
Sclerosis
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Pathologic Processes
Neurodegenerative Diseases
Nervous System Diseases
Neuromuscular Diseases
Spinal Cord Diseases
Central Nervous System Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases

ClinicalTrials.gov processed this record on September 26, 2016